tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

AtriCure price target raised to $53 from $51 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on AtriCure (ATRC) to $53 from $51 and keeps a Buy rating on the shares. The firm said they reported a very solid Q2, with strength across the rest of the business more than offsetting further degradation of US EPi-Sense/Hybrid. The target increase reflects comp group multiple expansion and increased expectations.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1